Commodore Capital
Latest statistics and disclosures from Commodore Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MRUS, XENE, NUVL, VERA, RYTM, and represent 41.83% of Commodore Capital's stock portfolio.
- Added to shares of these 10 stocks: ARVN (+$41M), SYRE (+$38M), NUVL (+$37M), PHVS (+$22M), CCCC (+$22M), ABVX (+$20M), NKTX (+$18M), Harpoon Therapeutics (+$17M), XENE (+$15M), SABS (+$13M).
- Started 8 new stock positions in Harpoon Therapeutics, ARVN, ABVX, DYN, PHVS, SABS, NKTX, CCCC.
- Reduced shares in these 10 stocks: Ambrx Biopharma (-$41M), RYTM (-$24M), IDYA (-$21M), CRNX (-$15M), CABA (-$14M), SNDX (-$14M), THRD (-$11M), DAWN (-$9.1M), SLNO (-$7.5M), VRDN (-$6.0M).
- Sold out of its positions in Ambrx Biopharma, CRNX, DAWN, IDYA, MRSN, SNDX.
- Commodore Capital was a net buyer of stock by $109M.
- Commodore Capital has $1.2B in assets under management (AUM), dropping by 35.10%.
- Central Index Key (CIK): 0001831942
Tip: Access up to 7 years of quarterly data
Positions held by Commodore Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Commodore Capital
Commodore Capital holds 32 positions in its portfolio as reported in the December 2023 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Merus N V (MRUS) | 11.3 | $131M | +7% | 4.7M | 27.50 |
|
| Xenon Pharmaceuticals (XENE) | 8.6 | $100M | +17% | 2.2M | 46.06 |
|
| Nuvalent Inc-a (NUVL) | 8.5 | $98M | +60% | 1.3M | 73.59 |
|
| Vera Therapeutics Cl A (VERA) | 7.3 | $84M | 5.5M | 15.38 |
|
|
| Rhythm Pharmaceuticals (RYTM) | 6.2 | $71M | -25% | 1.6M | 45.97 |
|
| Vaxcyte (PCVX) | 6.0 | $69M | 1.1M | 62.80 |
|
|
| Cabaletta Bio (CABA) | 3.7 | $43M | -24% | 1.9M | 22.70 |
|
| Immunovant (IMVT) | 3.6 | $42M | 1.0M | 42.13 |
|
|
| Miragen Therapeutics (VRDN) | 3.6 | $42M | -12% | 1.9M | 21.78 |
|
| Arvinas Ord (ARVN) | 3.6 | $41M | NEW | 1.0M | 41.16 |
|
| Spyre Therapeutics Com New (SYRE) | 3.5 | $41M | +1519% | 1.9M | 21.52 |
|
| Enliven Therapeutics (ELVN) | 3.5 | $40M | 2.9M | 13.84 |
|
|
| Cogent Biosciences (COGT) | 2.8 | $33M | 5.6M | 5.88 |
|
|
| Alpine Immune Sciences (ALPN) | 2.7 | $31M | +21% | 1.6M | 19.06 |
|
| Soleno Therapeutics (SLNO) | 2.4 | $28M | -21% | 700k | 40.25 |
|
| Celldex Therapeutics Com New (CLDX) | 2.4 | $28M | 702k | 39.66 |
|
|
| Celcuity (CELC) | 2.2 | $26M | +3% | 1.8M | 14.57 |
|
| Rayzebio | 2.1 | $24M | +32% | 384k | 62.17 |
|
| Pharvaris N V (PHVS) | 1.9 | $22M | NEW | 800k | 28.05 |
|
| C4 Therapeutics Com Stk (CCCC) | 1.9 | $22M | NEW | 3.8M | 5.65 |
|
| Abivax Sa Sponsored Ads (ABVX) | 1.8 | $20M | NEW | 1.9M | 10.70 |
|
| Nkarta (NKTX) | 1.6 | $18M | NEW | 2.7M | 6.60 |
|
| Kura Oncology (KURA) | 1.6 | $18M | -10% | 1.2M | 14.38 |
|
| Harpoon Therapeutics Com New | 1.5 | $17M | NEW | 1.5M | 11.37 |
|
| Akero Therapeutics (AKRO) | 1.1 | $13M | 565k | 23.35 |
|
|
| Sab Biotherapeutics (SABS) | 1.1 | $13M | NEW | 1.8M | 6.88 |
|
| Dyne Therapeutics (DYN) | 1.0 | $12M | NEW | 900k | 13.30 |
|
| Vistagen Therapeutics Ord (VTGN) | 0.7 | $8.1M | 1.6M | 5.14 |
|
|
| Third Harmonic Bio (THRD) | 0.7 | $7.8M | -58% | 707k | 10.97 |
|
| Adverum Biotechnologies | 0.7 | $7.5M | 10M | 0.75 |
|
|
| Apogee Therapeutics (APGE) | 0.6 | $7.0M | 250k | 27.94 |
|
|
| Dbv Technologies S A Sponsored Adr (DBVT) | 0.0 | $88k | 93k | 0.95 |
|
Past Filings by Commodore Capital
SEC 13F filings are viewable for Commodore Capital going back to 2020
- Commodore Capital 2023 Q4 filed Feb. 14, 2024
- Commodore Capital 2023 Q4 restated filed Feb. 14, 2024
- Commodore Capital 2023 Q3 filed Nov. 14, 2023
- Commodore Capital 2023 Q2 filed Aug. 14, 2023
- Commodore Capital 2023 Q1 filed May 15, 2023
- Commodore Capital 2022 Q4 filed Feb. 14, 2023
- Commodore Capital 2022 Q3 filed Nov. 14, 2022
- Commodore Capital 2022 Q2 filed Aug. 15, 2022
- Commodore Capital 2022 Q1 filed May 16, 2022
- Commodore Capital 2021 Q4 filed Feb. 14, 2022
- Commodore Capital 2021 Q3 filed Nov. 15, 2021
- Commodore Capital 2021 Q1 restated filed Oct. 14, 2021
- Commodore Capital 2021 Q2 restated filed Oct. 14, 2021
- Commodore Capital 2021 Q2 filed Aug. 16, 2021
- Commodore Capital 2021 Q1 filed May 17, 2021
- Commodore Capital 2020 Q4 filed Feb. 16, 2021